StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) shareholders

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1.0%
5M of 489M shares
Institutional holders
170
28 new, 42 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ari Zweiman
Joint filing with 683 Capital Management, LLC (9.99%), 683 Capital Partners, LP (9.99%)
49,868,5719.99%13G (passive)Jun 4, 2026
Michael S. Rosen
Joint filing with Context Capital Management, LLC (9.90%), William D. Fertig (9.90%) and 2 more
48,835,7889.90%13G (passive)Jun 4, 2026
DeepCurrents Investment Group LLC
Joint filing with Kai Zheng (7.70%), Dcig Gp LLC (5.70%) and 1 more
37,665,0737.70%13G (passive)Jun 4, 2026
Invus Public Equities Advisors, LLC
Joint filing with Invus Public Equities, L.P. (5.80%), Artal International S.C.A (5.80%) and 5 more
13,108,8805.80%13G (passive)Dec 14, 2023
FMR LLC
Joint filing with Abigail P. Johnson (10.90%)
667,46510.90%13G (passive)Oct 30, 2026
Opaleye Management Inc.
Joint filing with James Silverman (6.98%), Opaleye, L.P. (6.79%)
426,9896.98%13G (passive) amendmentSep 30, 2026
D. E. Shaw & Co., L.P.
Joint filing with D. E. Shaw & Co., L.L.C. (5.10%), David E. Shaw (5.10%)
312,0485.10%13D (active) amendmentSep 24, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GOSSValueChange% of portfolio
D. E. Shaw & Co., Inc.511,9910.10%$6.74M+507,1230.00%
683 Capital Management, LLC489,9860.10%$6.45M+427,4860.32%
DeepCurrents Investment Group LLC470,8140.10%$6.03MNew0.18%
Context Capital Management, LLC361,8310.07%$4.76MNew0.09%
Worth Venture Partners, LLC312,7240.06%$4.12MNew9.29%
Kalehua Capital Management LLC278,7340.06%$3.67M+57,3821.17%
Aqr Capital Management LLC195,3750.04%$2.57M+68,7880.00%
Gsa Capital Partners Llp187,3370.04%$2.47M+146,6590.16%
Wolverine Asset Management LLC161,1840.03%$2.12MNew0.02%
Renaissance Technologies LLC145,3740.03%$1.91M+130,1510.00%
Vanguard Capital Management LLC117,7000.02%$1.55M+2680.00%
ARCH Venture Management, LLC100,6990.02%$1.33M–0.12%
Barclays PLC97,9070.02%$1.29M+59,5850.00%
Octagon Capital Advisors LP96,8750.02%$1.28M–0.11%
BlackRock, Inc.95,8750.02%$1.26M−114,4600.00%
Arrowstreet Capital, Limited Partnership94,6670.02%$1.25MNew0.00%
Two Sigma Investments, LP92,9000.02%$1.22M+33,1390.00%
Samsara BioCapital, LLC90,2820.02%$1.19M–0.10%
Qube Research & Technologies Ltd88,3220.02%$1.16M+26,8500.00%
Corient Private Wealth LLC70,4090.01%$927.14K+20,5920.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20261705M1.0%28 / 6344 / 423M0M
Q1 20261852M0.5%47 / 7149 / 541M1M
Q4 20251952M0.5%49 / 6948 / 140M0M
Q3 20251642M0.5%56 / 4744 / 140M0M
Q2 20251232M0.5%33 / 4124 / 280M0M
Q1 20251182M0.4%23 / 3430 / 90M0M
Q4 20241052M0.4%18 / 3227 / 130M0M
Q3 20241002M0.4%17 / 2430 / 100M0M
Q2 2024942M0.5%11 / 3329 / 260M1M
Q1 20241093M0.5%26 / 2731 / 150M0M
Q4 2023983M0.6%22 / 3322 / 191M1M
Q3 2023953M0.5%31 / 3118 / 342M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

111 funds held GOSS in Q1 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GOSSValue% of fundAs of
Vanguard Total Stock Market Index Fund6,910,9341.41%$1.14M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund2,243,3050.46%$369.25K0.00%Jun 30, 2026
iShares Biotechnology ETF1,501,1160.31%$247.08K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund1,150,8570.24%$265.73K0.00%May 31, 2026
Schwab U.S. Small-Cap ETF986,8260.20%$227.86K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund977,0300.20%$225.60K0.00%May 31, 2026
Invesco RAFI US 1500 Small-Mid ETF556,3950.11%$94.31K0.00%Jul 31, 2026
Vanguard Health Care Index Fund541,9500.11%$125.14K0.00%May 31, 2026
Fidelity Total Market Index Fund381,1350.08%$88.00K0.00%May 31, 2026
BlackRock Health Sciences Opportunities Portfolio365,1990.07%$84.32K0.00%May 29, 2026
Fidelity Series Total Market Index Fund300,4210.06%$69.37K0.00%May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF294,0070.06%$48.39K0.00%Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund267,2450.05%$43.99K0.00%Jun 30, 2026
Eventide Small Cap ETF204,5510.04%$34.67K0.10%Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund180,2560.04%$41.62K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Faheem HasnainPresident & CEO, Director6,245,8661.28%Aug 26, 2026
Caryn PetersonChief Development Officer259,3330.05%Aug 26, 2026
Waage ChristianEVP, Tech Ops and Admin882,1750.18%Aug 26, 2026
Bryan GiraudoCOO/CFO869,7470.18%Aug 26, 2026
Robert Paul Smith JRChief Commercial Officer285,8980.06%Aug 26, 2026
Richard ArandaChief Medical Officer465,6450.10%Mar 20, 2026
Russell J. CoxDirector7,2000.00%Sep 25, 2026
John D. QuiselDirector––Sep 25, 2026
Gregory Austin CiongoliDirector––Sep 25, 2026
Skye DrynanDirector––Sep 25, 2026
Sandra MilliganDirector90,0500.02%Sep 25, 2026
Steven D. NathanDirector––Sep 25, 2026
Thomas O. DanielDirector38,0950.01%Sep 25, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Robert Paul Smith JR
Chief Commercial Officer
Jan 2, 2026Award+93,750––260,898
Caryn Peterson
EVP, Regulatory Affairs
Jan 2, 2026Award+84,500––259,333
Richard Aranda
Chief Medical Officer
Jan 2, 2026Award+93,750––463,106
Faheem Hasnain
President & CEO, Director
Jan 2, 2026Award+280,000––837,793
Waage Christian
EVP, Tech Ops and Admin
Jan 2, 2026Award+84,500––814,061
Bryan Giraudo
COO/CFO
Jan 2, 2026Award+115,750––389,737
Faheem Hasnain
President & CEO, Director
Oct 1, 2025Award+437,500––557,793
Richard Aranda
Chief Medical Officer
Oct 1, 2025Award+162,500––369,356
Caryn Peterson
EVP, Regulatory Affairs
Oct 1, 2025Award+125,000––174,833
Bryan Giraudo
COO/CFO
Oct 1, 2025Award+181,250––273,987
Robert Paul Smith JR
Chief Commercial Officer
Oct 1, 2025Award+162,500––162,500
Waage Christian
EVP, Tech Ops and Admin
Oct 1, 2025Award+125,000––710,934
Sandra Milligan
Director
Aug 19, 2025Buy+26,050$1.92$50.02K58,050
Richard Aranda
Chief Medical Officer
Jun 24, 2024Sale−1,908$0.66$1.26K196,891
Faheem Hasnain
President & CEO, Director
Jun 21, 2024Buy+372,000$0.67$249.24K5,408,073
Bryan Giraudo
COO/CFO
Jun 18, 2024Buy+100,000$0.59$59.00K480,010
Robert Paul Smith JR
Chief Commercial Officer
Jun 17, 2024Buy+25,000$0.60$15.00K25,000
Waage Christian
EVP, Tech Ops and Admin
Mar 27, 2024Sale−6,430$1.16$7.46K585,934
Bryan Giraudo
COO/CFO
Mar 27, 2024Sale−6,430$1.16$7.46K92,737
Faheem Hasnain
President & CEO, Director
Mar 27, 2024Sale−23,172$1.16$26.88K120,293
Richard Aranda
Chief Medical Officer
Mar 18, 2024Sale−4,018$1.33$5.34K198,799
Caryn Peterson
EVP, Regulatory Affairs
Mar 18, 2024Sale−4,018$1.33$5.34K49,833
Sandra Milligan
Director
Nov 15, 2023Buy+32,000$0.79$25.28K32,000
Bryan Giraudo
COO/CFO
Nov 13, 2023Buy+200,000$0.56$112.00K380,010
Faheem Hasnain
President & CEO, Director
Jul 24, 2023Award+540,176$1.82$983.12K5,036,073
Waage Christian
EVP, Tech Ops and Admin
Jul 24, 2023Award+13,504$1.82$24.58K45,892
Bryan Giraudo
COO/CFO
Jul 24, 2023Award+54,020$1.82$98.32K180,010
Richard Aranda
Chief Medical Officer
Jun 22, 2023Sale−1,814$1.29$2.34K197,574
Bryan Giraudo
COO/CFO
Apr 4, 2023Buy+55,000$1.02$56.10K125,990
Faheem Hasnain
President & CEO, Director
Mar 22, 2023Buy+440,500$1.14$502.17K4,495,897
Faheem Hasnain
President & CEO, Director
Mar 21, 2023Buy+269,389$1.20$323.27K4,055,397
Waage Christian
EVP, Tech Ops and Admin
Mar 20, 2023Buy+18,500$1.20$22.20K32,388
Faheem Hasnain
President & CEO, Director
Mar 20, 2023Buy+168,683$1.03$173.74K3,786,008
Bryan Giraudo
COO/CFO
Mar 20, 2023Buy+50,000$0.97$48.50K70,990
Caryn Peterson
EVP, Regulatory Affairs
Mar 16, 2023Sale−7,564$1.10$8.32K53,851
Laura Carter
Chief Scientific Officer
Mar 16, 2023Sale−6,029$1.10$6.63K76,263
Richard Aranda
Chief Medical Officer
Mar 16, 2023Sale−7,563$1.10$8.32K199,388
Laura Carter
Chief Scientific Officer
Oct 24, 2022Sale−4,876$12.07$58.85K82,292
Caryn Peterson
EVP, Regulatory Affairs
Oct 24, 2022Sale−4,757$12.07$57.42K61,415
Richard Aranda
Chief Medical Officer
Oct 24, 2022Sale−4,757$12.07$57.42K205,430
Laura Carter
Chief Scientific Officer
Oct 24, 2022Sale−4,876$12.07$58.85K82,292
Laura Carter
Chief Scientific Officer
Jul 15, 2022Buy+6,934$7.21$49.99K87,168
Waage Christian
EVP, Tech Ops and Admin
Jul 15, 2022Buy+6,934$7.21$49.99K13,888
Bryan Giraudo
COO/CFO
Jul 15, 2022Buy+13,869$7.21$100.00K20,990
Faheem Hasnain
President & CEO, Director
Jul 15, 2022Buy+138,696$7.21$1,000.00K3,617,325
Laura Carter
Chief Scientific Officer
Jul 1, 2022Sale−8,808$8.25$72.67K80,234
Richard Aranda
Chief Medical Officer
Jun 22, 2022Sale−1,778$6.88$12.23K209,897
Laura Carter
Chief Scientific Officer
May 4, 2022Sale−1,262$7.20$9.09K89,042
Waage Christian
EVP, Tech Ops and Admin
Mar 23, 2022Sale−10,722$8.92$95.64K579,008
Faheem Hasnain
President & CEO, Director
Mar 23, 2022Sale−19,035$8.92$169.79K143,465
Bryan Giraudo
COO/CFO
Mar 23, 2022Sale−10,722$8.92$95.64K99,167
Laura Carter
Chief Scientific Officer
Mar 16, 2022Sale−5,002$8.28$41.42K90,304
Richard Aranda
Chief Medical Officer
Mar 16, 2022Sale−6,278$8.28$51.98K211,675
Caryn Peterson
EVP, Regulatory Affairs
Mar 16, 2022Sale−6,279$8.28$51.99K66,172
Laura Carter
Chief Scientific Officer
Oct 25, 2021Sale−2,377$12.25$29.12K95,306
Richard Aranda
Chief Medical Officer
Oct 25, 2021Sale−2,377$12.25$29.12K217,432
Caryn Peterson
EVP, Regulatory Affairs
Oct 25, 2021Sale−2,377$12.25$29.12K72,451
Laura Carter
Chief Scientific Officer
Jun 30, 2021Award+25,000––97,683
Richard Aranda
Chief Medical Officer
Jun 21, 2021Award+15,000––219,809
Laura Carter
Chief Scientific Officer
May 3, 2021Award+10,820––72,683

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.28%
1M shares short
Days to cover
7.5
At 0M shares a day
Change since last report
-6.8%
From 1M shares
Short volume, 20 days
51.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gossamer Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,535,808 shares on Sep 11, 2026 over the last 90 days.

See a number that looks wrong?